Xeris Pharmaceuticals stock analysis
Want to see XERS full AI Analyst Report?
Xeris Pharmaceuticals (XERS) Stock Price & Analysis
XERS Stock Chart & Stats
- Day’s Range
- $16.54 - $16.98
- 52-Week Range
- $5.25 - $16.98
- Previous Close
- $16.66
- Volume
- N/A
- Average Volume (3M)
- 3.05M
- Market Cap
- $3.05B
- Enterprise Value
- $1.91B
- Total Cash (Recent Filing)
- $131.08M
- Total Debt (Recent Filing)
- $226.07M
- Price to Earnings (P/E)
- ―
- Beta
- 0.82
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- 0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial Momentum
Strong growth across the commercial portfolio is expanding Xeris’s revenue base and supports operating leverage as the business scales. Raised full-year guidance indicates management sees momentum continuing beyond a single quarter, strengthening the company’s medium-term growth profile.
Cash Generation And Gross Margins
High gross margins combined with strong operating and free cash flow demonstrate that Xeris’s approved-product model is producing meaningful cash while revenue grows. This financial productivity can support commercial investment, pipeline development, and greater self-funding capacity over the next several quarters.
Protected Pipeline And Intellectual Property
Strengthened patent protection gives XP-8121 a potentially durable period of market exclusivity if development succeeds. Advancing toward a pivotal study also creates a credible longer-term growth option that could broaden Xeris’s portfolio and leverage its existing commercial infrastructure.
Bears Say
Elevated Balance Sheet Leverage
High leverage remains a material constraint on financial flexibility despite improving equity and cash generation. Debt relative to the equity base could limit investment choices, increase sensitivity to any slowdown in growth, and make it harder to absorb weaker profitability or unexpected execution demands.
GAAP Profitability Is Not Yet Durable
Xeris has improved operating profitability, but the continuing TTM net loss shows that bottom-line earnings have not yet become consistently positive. Until this converts into durable net income, shareholder returns remain less predictable and the company remains more dependent on execution and cash-flow strength.
Reimbursement And Access Friction
Ongoing prior authorization requirements can slow patient starts and add work for clinicians, patients, and Xeris’s support organization. Because management does not expect the issue to change immediately, access friction may continue limiting Recorlev conversion and raise the commercial resources needed to sustain growth.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
What is Xeris Pharmaceuticals’s market cap?
When is Xeris Pharmaceuticals’s upcoming earnings report date?
How were Xeris Pharmaceuticals’s earnings last quarter?
Is Xeris Pharmaceuticals overvalued?
Does Xeris Pharmaceuticals pay dividends?
What is Xeris Pharmaceuticals’s EPS estimate?
How many shares outstanding does Xeris Pharmaceuticals have?
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Xeris Pharmaceuticals Stock Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Shannon
- Employees
- 435
- Website
- www.xerispharma.com
- Address
- 1375 West Fulton Street, Chicago, IL, 60607, US
Xeris Pharmaceuticals (XERS) Earnings & Revenues
XERS Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with record third-quarter revenue, substantial Recorlev growth, improving Gvoke prescription demand, continued KEVEYIS growth, higher Adjusted EBITDA and net income, strengthened intellectual property, and raised 2026 and 2030 revenue outlooks. The primary negative items were Gvoke net revenue being reduced by a $4 million one-time Medicaid gross-to-net adjustment, ongoing prior authorization requirements for Recorlev, and higher commercial and operating expenses.
View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |














